Promising ALS Trial Results Bolster Buy Rating for MaaT Pharma Amidst Strategic Oncology Focus

Clémence Thiers, an analyst from Stifel Nicolaus, maintained the Buy rating on MaaT Pharma (MAAT – Research Report). The associated price target remains the same with €22.00.

Clémence Thiers’s rating is based on the promising results from MaaT Pharma’s recent clinical trial involving their product MaaT033 in the treatment of Amyotrophic Lateral Sclerosis (ALS). The trial demonstrated a numerical improvement in ALSFRS-R slopes post-treatment, indicating a potential positive impact on disease progression. Importantly, the study confirmed the safety and tolerability of MaaT033, with no adverse changes in neurofilament levels, a critical biomarker for neurodegeneration.
Although the neurodegeneration indication is not yet included in the company’s valuation due to its early exploration stage, these initial findings are encouraging. The trial’s results suggest that MaaT033 could influence disease trajectory through microbiome modulation, which is a novel approach in ALS treatment. MaaT Pharma’s strategic focus remains on oncology, but the ALS data provide a strong case for further investigation and potential partnerships to expand their research in this high-interest area. These factors collectively support the Buy rating given by Clémence Thiers.

MAAT’s price has also changed moderately for the past six months – from EUR7.780 to EUR5.340, which is a -31.36% drop .